Minoryx Therapeutics

company

About

Minoryx Therapeutics offers pharmacological chaperones, which are small molecule drugs used for the treatment of genetic diseases.

  • 11 - 50

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
€25M
Industries
Biotechnology,Genetics,Medical,Pharmaceutical
Founded date
Jan 1, 2011
Number Of Employee
11 - 50
Operating Status
Active

Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€25M
Minoryx Therapeutics has raised a total of €25M in funding over 2 rounds. Their latest funding was raised on Oct 30, 2020 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 30, 2020 Debt Financing €25M 1 European Investment Bank Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Minoryx Therapeutics is funded by 1 investors. European Investment Bank are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Debt Financing